Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi‐stakeholder, international workshop
| Autor: | Andrew Bruce, Carla Deakin, Nicholas Latimer, Lloyd Sansom, Chris Henshall, Daniel Pollard, Robyn L. Ward, Adrian Towse |
|---|---|
| Přispěvatelé: | Latimer, Nicholas R, Pollard, Daniel, Towse, Adrian, Henshall, Chris, Sansom, Lloyd, Ward, Robyn L, Bruce, Andrew, Deakin, Carla |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
economic evaluation
Cost effectiveness media_common.quotation_subject costs Medical Oncology Health informatics combination therapy Health administration Value‐based pricing Willingness to pay Value-based pricing Neoplasms Cost‐effectiveness pricing cancer Medicine Humans Marketing Combination therapy media_common Cancer business.industry Health Policy cost‐effectiveness Payment reimbursement Economic evaluation Reimbursement Costs Regimen Costs and Cost Analysis Public aspects of medicine RA1-1270 business value‐based pricing Pricing Research Article |
| Zdroj: | BMC Health Services Research BMC Health Services Research, Vol 21, Iss 1, Pp 1-9 (2021) |
| ISSN: | 1472-6963 |
| Popis: | Background It is increasingly common for two or more treatments for cancer to be combined as a single regimen. Determining value and appropriate payment for such regimens can be challenging. This study discusses these challenges, and possible solutions. Methods Stakeholders from around the world attended a 2-day workshop, supported by a background paper. This study captures key outcomes from the discussion, but is not a consensus statement. Results Workshop attendees agreed that combining on-patent treatments can result in affordability and value for money challenges that delay or deny patient access to clinically effective treatments in many health systems. Options for addressing these challenges include: (i) Increasing the value of combination therapies through improved clinical development; (ii) Willingness to pay more for combinations than for single drugs offering similar benefit, or; (iii) Aligning the cost of constituent therapies with their value within a regimen. Workshop attendees felt that (i) and (iii) merited further discussion, whereas (ii) was unlikely to be justifiable. Views differed on the feasibility of (i). Key to (iii) would be systems allowing different prices to apply to different uses of a drug. Conclusions Common ground was identified on immediate actions to improve access to combination regimens. These include an exploration of the legal challenges associated with price negotiations, and ensuring that pricing systems can support implementation of negotiated prices for specific uses. Improvements to clinical development and trial design should be pursued in the medium and longer term. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink